Palatin Technologies Inc Quick Ratio (PTN) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Palatin Technologies Inc   (NYSEAMER: PTN)

Palatin Technologies Inc 's Quick Ratio

PTN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Palatin Technologies Inc 's Cash & cash equivalent, this led to improvement in Palatin Technologies Inc 's Quick Ratio to 4.01, Quick Ratio remained below Palatin Technologies Inc average.

Within Major Pharmaceutical Preparations industry 196 other companies have achieved higher Quick Ratio than Palatin Technologies Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 194 to 692.

Explain Quick Ratio?
How much Cash & cash equivalents PTN´s has?
What are PTN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PTN Quick Ratio (Mar 31 2026)
Q3		 (Dec 31 2025)
Q2		 (Sep 30 2025)
Q1		 (Jun 30 2025)
Q4		 (Mar 31 2025)
Q3
Y / Y Current Liabilities Change -74.76 % -33.75 % -18.01 % -17.06 % 17.76 %
Y / Y Cash & cash equivalent Change - - - - -
Quick Ratio MRQ 4.01 2.29 - - -
PTN's Total Ranking # 692 # 194 # 0 # 0 # 0
Seq. Current Liabilities Change -59.95 % -21.68 % 0.95 % -20.29 % 5.12 %
Seq. Cash & cash equivalent Change -29.82 % - - - -



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 197
Healthcare Sector # 321
Overall Market # 692


Quick Ratio Statistics
High Average Low
66.52 7.88 0.2
(Dec 31 2019)   (Jun 30 2023)




Financial Statements
Palatin Technologies Inc 's Current Liabilities $ 3 Millions Visit PTN's Balance sheet
Palatin Technologies Inc 's Cash & cash equivalent $ 10 Millions Visit PTN's Balance sheet
Source of PTN's Sales Visit PTN's Sales by Geography


Cumulative Palatin Technologies Inc 's Quick Ratio

PTN's Quick Ratio for the trailling 12 Months

PTN Quick Ratio

 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months
Y / Y Current Liabilities TTM Growth -36.2 % -13.65 % -9.04 % -12.84 % -19.28 %
Y / Y Cash & cash equivalent TTM Growth 171.05 % 59.27 % - - 203.69 %
Quick Ratio TTM 0.99 0.45 - - 0.23
Total Ranking TTM # 2942 # 1065 # 0
Seq. Current Liabilities TTM Growth -23.13 % -9.04 % -4.74 % -4.21 % 4.03 %
Seq. Cash & cash equivalent TTM Growth 70.18 % - - - 0 %

Quick ratio ranking by company, industry and sector >> Back to PTN Financial Strength Comparisons >> Go to Compare PTN Quick Ratio to its Competitors

On the trailing twelve months basis PTN Cash & cash equivalent faded by -29.82 % in Q3 2026 year on year, while Current Liabilities dropped to $3 millions, this led to increase in in Palatin Technologies Inc 's Quick Ratio to 0.99, Quick Ratio remained below PTN average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 392 other companies have achieved higher Quick Ratio than Palatin Technologies Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from 1065 to 2942.

Explain Quick Ratio?
How much Cash & cash equivalents PTN´s has?
What are PTN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 393
Healthcare Sector # 808
Within the Market # 2942


trailing twelve months Quick Ratio Statistics
High Average Low
34.95 6.82 0.06
(Jun 30 2020)  




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Olema Pharmaceuticals Inc   10.94 $ 505.347  Millions$ 46.211  Millions
Wave Life Sciences Ltd   10.93 $ 544.591  Millions$ 49.831  Millions
Avalyn Pharma Inc   10.92 $ 123.127  Millions$ 11.280  Millions
Ovid Therapeutics Inc   10.88 $ 155.522  Millions$ 14.289  Millions
Abcellera Biologics Inc   10.81 $ 427.669  Millions$ 39.551  Millions
Enveric Biosciences Inc   10.66 $ 4.909  Millions$ 0.461  Millions
Ideaya Biosciences Inc   10.41 $ 671.201  Millions$ 64.481  Millions
Immuneering Corporation  10.37 $ 47.322  Millions$ 4.561  Millions
Synlogic Inc   10.35 $ 14.105  Millions$ 1.363  Millions
Spero Therapeutics Inc   10.23 $ 56.129  Millions$ 5.489  Millions
Cytomx Therapeutics Inc   10.19 $ 346.707  Millions$ 34.023  Millions
Revelation Biosciences Inc   9.96 $ 14.113  Millions$ 1.417  Millions
Nektar Therapeutics  9.85 $ 568.604  Millions$ 57.708  Millions
Lipocine Inc   9.78 $ 24.729  Millions$ 2.528  Millions
Boundless Bio Inc   9.69 $ 92.847  Millions$ 9.583  Millions
Promis Neurosciences inc   9.65 $ 63.848  Millions$ 6.615  Millions
Newamsterdam Pharma Company N v   9.54 $ 636.105  Millions$ 66.696  Millions
Silo Pharma Inc  9.53 $ 6.032  Millions$ 0.633  Millions
Kailera Therapeutics Inc   9.47 $ 519.174  Millions$ 54.836  Millions
Erasca Inc   9.14 $ 243.788  Millions$ 26.664  Millions
Anixa Biosciences Inc   9.12 $ 13.686  Millions$ 1.501  Millions
Diamedica Therapeutics Inc   9.11 $ 51.331  Millions$ 5.633  Millions
Acrivon Therapeutics Inc   8.84 $ 97.737  Millions$ 11.054  Millions
Medicinova Inc   8.83 $ 27.329  Millions$ 3.096  Millions
Neuphoria Therapeutics Inc   8.81 $ 13.327  Millions$ 1.513  Millions
Milestone Pharmaceuticals Inc   8.80 $ 184.216  Millions$ 20.944  Millions
Nuvation Bio Inc   8.74 $ 533.729  Millions$ 61.089  Millions
Spyre Therapeutics Inc   8.71 $ 741.467  Millions$ 85.162  Millions
First Tracks Biotherapeutics Inc   8.65 $ 286.455  Millions$ 33.112  Millions
Immix Biopharma Inc   8.59 $ 90.579  Millions$ 10.540  Millions

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.